Intersections and Clinical Translations of Diabetes Mellitus with Cancer Promotion, Progression and Prognosis

References

• Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care. 2016;39(2):179–186.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Epstein S, Corkey B, et al. A unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab. 2017;28(9):645–655.
   PubMed Web of Science ®Google Scholar
• Dankner R, Boffetta P, Balicer RD, et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016 Jun 15;183(12):1098–1106.
   PubMed Web of Science ®Google Scholar
• Noto H, Goto A, Tsujimoto T, et al. Latest insights into the risk of cancer in diabetes. J Diabetes Investig. 2013;4(3):225–232.
   PubMed Web of Science ®Google Scholar
• Pomerantz MM, Ahmadiyeh N, Jia L, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet. 2009 Aug;41(8):882–884.
   PubMed Web of Science ®Google Scholar
• Sacerdote C, Ricceri F. Epidemiological dimensions of the association between type 2 diabetes and cancer: A review of observational studies. Diabetes Res Clin Pract. 2018 Mar 27;143:369–377. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–2764.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriquez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Frayling TM, Colhoun H, Florez JC. A genetic link between type 2 diabetes and prostate cancer. Diabetologia. 2008 Oct;51(10):1757–1760.
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007 Aug;39(8):977–983.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Salmerón M, Chocarro-Calvo A, García-Martínez JM, et al. Epidemiological bases and molecular mechanisms linking obesity, diabetes, and cancer. Endocrinol Diabetes Nutr. 2017 Feb;64(2):109–117.
   PubMed Web of Science ®Google Scholar
• Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018 Aug;67(8):1471–1480.
   PubMed Web of Science ®Google Scholar
• de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer. 2014 Apr 29;110(9):2361–2368.
   PubMed Web of Science ®Google Scholar
• Garcia-Jimenez C, Gutierrez-Salmeron M, Chocarro-Calvo A, et al. From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer. 2016;114:716–722.
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101:48–60.
   PubMed Web of Science ®Google Scholar
• Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer. J Endocrinol Invest. 2016 Dec;39(12):1365–1376.
   PubMed Web of Science ®Google Scholar
• Wang L, Cai S, Teng Z, et al. Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis. Diagn Pathol. 2013 Oct;31(8):180.
   Web of Science ®Google Scholar
• Wellen KE, Thompson CB. Cellular metabolic stress: Considering how cells respond to nutrient excess. Mol Cell. 2010 Oct 22;40(2):323–332.
   PubMed Web of Science ®Google Scholar
• Widschwendter P, Friedl TW, Schwentner L, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res. 2015;17:129.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhu J, Prokop LJ, et al. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Sci Rep. 2015;5:10147.
   PubMed Web of Science ®Google Scholar
• Zhou XH, Qiao Q, Zethelius B. DECODE study group. diabetes, prediabetes and cancer mortality. Diabetologia. 2010 Sep;53(9):1867–1876.
   PubMed Web of Science ®Google Scholar
• Masur K, Vetter C, Hinz A, et al. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer. 2011 Jan 18;104(2):345–352.
   PubMed Web of Science ®Google Scholar
• Cignarelli A, Genchi VA, Caruso I, et al. Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’. Diabetes Res Clin Pract. 2018 Sep;143:378–388.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15:484–498.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Incio J, Shankaraiah RC, et al. Obesity and Cancer: An Angiogenic and Inflammatory Link. Microcirculation (New York, NY : 1994). 2016;23(3):191–206.
   PubMed Web of Science ®Google Scholar
• Donga E, Dekkers OM, Corssmit EPM, et al. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol. 2015;173:101–109.
   PubMed Web of Science ®Google Scholar
• Martin SD, McGee SL. Metabolic reprogramming in type 2 diabetes and the development of breast cancer. J Endocrinol. 2018;237(2):R35–R46.
   PubMed Web of Science ®Google Scholar
• Green AS, Chapuis N, Lacombe C, et al. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle. 2011 Jul 1;10(13):2115–2120.
   PubMed Web of Science ®Google Scholar
• Liu X, Chhipa RR, Pooya S, et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMP. Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):E435–44.
   PubMed Web of Science ®Google Scholar
• Sciacca L, Vigneri R, Tumminia A, et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23:808e15.
   Web of Science ®Google Scholar
• Yang J, Nishihara R, Zhang X, et al. Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer? J Diabetes Complications. 2017 Jul;31(7):1228–1236.
   PubMed Web of Science ®Google Scholar
• Li D. Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes. 2011;3:320–327.
   PubMed Web of Science ®Google Scholar
• Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001 Sep;11(9):372–377.
   PubMed Web of Science ®Google Scholar
• Williams M, Caino MC. Mitochondrial dynamics in type 2 diabetes and cancer. Front Endocrinol (Lausanne). 2018;9:211.
   PubMed Web of Science ®Google Scholar
• Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther. 2012 Jun;14(Suppl 1):S68–74.
   PubMed Web of Science ®Google Scholar
• Volkmar M, Dedeurwaerder S, Cunha DA, et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. Embo J. 2012;31(6):1405–1426.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003 Jun 5;348(23):2294–2303.
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Wu D, Hu D, Chen H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 2018 Jul;559(7715):637–641.
   PubMed Web of Science ®Google Scholar
• Yu X, Mao W, Zhai Y, et al. Anti-tumor activity of metformin: from metabolic and epigenetic perspectives. Oncotarget. 2017;17;8(3):5619–5628.
   Google Scholar
• Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–323.
   PubMed Web of Science ®Google Scholar
• Duval A, Rolland S, Tubacher E, et al. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res. 2000 Jul 15;60(14):3872–3879.
   PubMed Web of Science ®Google Scholar
• Tuupanen S, Turunen M, Lehtonen R. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet. 2009;41:885–890.
   PubMed Web of Science ®Google Scholar
• Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med. 2011;365:611–619.
   PubMed Web of Science ®Google Scholar
• Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40:638–645.
   PubMed Web of Science ®Google Scholar
• Devaney JM, Gordish-Dressman H, Harmon BT, et al. AKT1 polymorphisms are associated with risk for metabolic syndrome. Hum Genet. 2011;129:129–139.
   PubMed Web of Science ®Google Scholar
• Pal A, Barber TM, Van de Bunt M, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012;367:1002–1101.
   PubMed Web of Science ®Google Scholar
• Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010 Feb;33(2):322–326.
   PubMed Web of Science ®Google Scholar
• Seabloom DE, Galbraith AR, Haynes AM, et al. Fixed-Dose combinations of pioglitazone and metformin for lung cancer prevention. Cancer Prev Res (Phila). 2017 Feb;10(2):116–123.
   PubMed Web of Science ®Google Scholar
• Peng WF, Bai F, Shao K, et al. The key genes underlying pathophysiology association between the type 2-diabetic and colorectal cancer. J Cell Physiol. 2018 Nov;233(11):8551–8557.
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25(12):1476–1481.
   PubMed Web of Science ®Google Scholar
• Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30:1026–1032.
   PubMed Web of Science ®Google Scholar
• He X, Esteva FJ, Ensor J, et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012;23:1771–1780.
   PubMed Web of Science ®Google Scholar
• Strongman H, Korhonen P, Williams R, et al. Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. 2017 May 29;5(1):e000364.
   PubMed Web of Science ®Google Scholar
• Wu CW, Farrell GC, Yu J. Functional role of peroxisome-proliferator-activated receptor gamma in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1665–1669.
   PubMed Web of Science ®Google Scholar
• Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol. 2017 Feb;14(2):85–99.
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Yakubovich N, Dagenais GR, et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care. 2014;37:1360–1366.
   PubMed Web of Science ®Google Scholar
• But A, De Bruin ML, Bazelier MT, et al. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia. 2017;60:1691e703.
   Web of Science ®Google Scholar
• Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451–1461.
   PubMed Web of Science ®Google Scholar
• Vora J, Ray K, Kosiborod M, et al. Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. J Diabetes Complications. 2017 Sep;31(9):1451–1457.
   PubMed Web of Science ®Google Scholar
• Andrzejewski S, Siegel PM, St-Pierre J. Metabolic profiles associated with metformin efficacy in cancer. Front Endocrinol. 2018 Aug;21(9):372.
   Web of Science ®Google Scholar
• Chang C-H, Lin J-W, Wu L-C, et al. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 July;97(7):E1170–E1175.
   PubMed Web of Science ®Google Scholar
• Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116:1938–1946.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–1777.
   PubMed Web of Science ®Google Scholar
• Wu JW, Filion KB, Azoulay L, et al. Effect of long-acting insulin analogs on the risk of cancer: a systematic review of observational studies. Diabetes Care. 2016 Mar;39(3):486–494.
   PubMed Web of Science ®Google Scholar
• Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011;29:47–53.
   PubMed Web of Science ®Google Scholar
• Villani LA, Smith BK, Marcinko K, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5:1048–1056.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American college of physicians. Ann Intern Med. 2018;168(8):569–576.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, March 9, 2018. The American diabetes association®, the American association of clinical endocrinologists, the American association of diabetes educators and the endocrine society strongly disagree with the American college of physicians’ guidance for higher blood glucose targets for people with type 2 diabetes (press release). [cited 2018 Jun 05]. Available from http://www.diabetes.org/newsroom/press-releases/2018/joint-acp-guidance-response.html
   Google Scholar
• Schwartz SS, Herman ME American college of physicians misses A1C target. Diabetes in Control, 2018 May 5. Available from: http://www.diabetesincontrol.com/american-college-of-physicians-misses-a1c-target/
   Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Luoh SW, Flaherty KT. When tissue is no longer the issue: tissue-agnostic cancer therapy comes of age. Ann Intern Med. 2018 Aug 21;169(4):233–239.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhao M, Li J, et al. Obesity-associated digestive cancers: A review of mechanisms and interventions. Tumour Biol. 2017 Mar;39(3):1010428317695020.
   Google Scholar